- LRK-A drives monotherapy anti-tumor activity, including complete tumor regressions, in CRC patient samples and an in vivo model
- IND-enabling studies are under way; Larkspur is moving rapidly toward clinical development
WATERTOWN, MA, USA I March 28, 2024 I Larkspur Biosciences, a company pioneering a new wave in cancer therapy by targeting cancer-intrinsic drivers of immune evasion, announced that it will present positive preclinical efficacy data for LRK-A, Larkspur’s novel, lead investigational therapy targeting the lipid kinase PIP4K2C, in primary human tumor samples and an in vivo model of colorectal cancer (CRC). The data will be featured in a poster presentation at the 115th Annual Meeting of the American Association for Cancer Research (AACR 2024) in San Diego, CA.
“Larkspur Biosciences pursues novel targets inside the cancer, like PIP4K2C, that prevent the immune system from seeing and attacking it. Our data at AACR 2024 demonstrate the potential of targeted PIP4K2C degradation to uncloak the tumor and support the advancement of our PIP4K2C degrader program as a monotherapy to treat CRC and other solid tumors,” said Catherine Sabatos-Peyton, PhD, CEO of Larkspur Biosciences. “Using LarkXCRC, our proprietary bioinformatics platform, Larkspur developed a patient biomarker strategy to select the patients most likely to respond to LRK-A. This strategy enables the design of clinical trials that are smaller, faster, and have a higher probability of success.”
CRC is the second leading cause of cancer-related deaths in the U.S.; in people under the age of 50, CRC is the top cause of cancer mortality in men and second cause in women1. Larkspur aims to shift the treatment paradigm – which hasn’t meaningfully changed in decades – by effectively activating the immune system against tumors by targeting PIP4K2C.
“PIP4K2C is part of the ‘dark kinome’ – the approximately 25% of kinases with unknown or poorly understood functions,” said Nathanael Gray, PhD, professor of chemical and systems biology at Stanford University and co-founder of Larkspur. “My co-founders and I jointly discovered that PIP4K2C acts in both cancer cells and immune cells to get tumor antigens presented to the right immune cells. Lew Cantley discovered that uniquely among the family of PI5P4K isoforms, mice that were germline knockouts of PIP4K2C broke tolerance, a hallmark of key targets that drive cancer immune evasion. Larkspur’s AACR 2024 presentation sheds further light on PIP4K2C by offering key evidence for its role as a cancer-intrinsic driver of immune evasion in both tumor and immune cells, and demonstrating the therapeutic promise of degrading the target in CRC and other solid tumors.”
Presentation details:
Published Abstract Number: 5574
Title: “Degradation of PIP4K2C by novel bivalent functional degrader LRK-A induces tumor regression in CRC”
Session Category / Session Title: Tumor Biology / Tumor-Immune System Cross-Talk
Session Date and Time: Tuesday, April 9, 1:30-5:30 pm PDT
Location / Poster Board Number: Poster Section 12 / Number 30
Presenter: Eva d’Hennezel, PhD, Director of Immunology, Larkspur Biosciences
About Larkspur Biosciences
Larkspur Biosciences is pioneering a new wave in cancer therapy that stops immune evasion where it starts: in the tumor. Larkspur’s approach targets cancer-intrinsic factors that tumors use to escape immune detection and control to develop new treatment options for patients who cannot be helped by current therapies. The company is advancing first-in-class programs designed to eliminate tumor “bottlenecks” that drive immune evasion in colorectal cancer (CRC) and beyond. LarkX, the company’s proprietary bioinformatics platform, couples machine learning with tumor genetics to discover immune evasion pathways that originate in the tumor and enrich clinical strategies for potential responders to its therapies across multiple types of cancer. Larkspur’s founders include Lewis C. Cantley, PhD, professor of medicine at Dana-Farber Cancer Institute, professor of cell biology at Harvard Medical School; Vijay K. Kuchroo, DVM, PhD, professor of neurology at Harvard Medical School, senior scientist at Brigham and Women’s Hospital; and Nathanael Gray, PhD, professor of chemical and systems biology at Stanford University.
Visit us at Larkspur.bio and follow us on LinkedIn and X.
1 American Cancer Society. Cancer Facts & Figures 2024. Atlanta: American Cancer Society; 2024.
SOURCE: Larkspur Biosciences
Post Views: 573
- LRK-A drives monotherapy anti-tumor activity, including complete tumor regressions, in CRC patient samples and an in vivo model
- IND-enabling studies are under way; Larkspur is moving rapidly toward clinical development
WATERTOWN, MA, USA I March 28, 2024 I Larkspur Biosciences, a company pioneering a new wave in cancer therapy by targeting cancer-intrinsic drivers of immune evasion, announced that it will present positive preclinical efficacy data for LRK-A, Larkspur’s novel, lead investigational therapy targeting the lipid kinase PIP4K2C, in primary human tumor samples and an in vivo model of colorectal cancer (CRC). The data will be featured in a poster presentation at the 115th Annual Meeting of the American Association for Cancer Research (AACR 2024) in San Diego, CA.
“Larkspur Biosciences pursues novel targets inside the cancer, like PIP4K2C, that prevent the immune system from seeing and attacking it. Our data at AACR 2024 demonstrate the potential of targeted PIP4K2C degradation to uncloak the tumor and support the advancement of our PIP4K2C degrader program as a monotherapy to treat CRC and other solid tumors,” said Catherine Sabatos-Peyton, PhD, CEO of Larkspur Biosciences. “Using LarkXCRC, our proprietary bioinformatics platform, Larkspur developed a patient biomarker strategy to select the patients most likely to respond to LRK-A. This strategy enables the design of clinical trials that are smaller, faster, and have a higher probability of success.”
CRC is the second leading cause of cancer-related deaths in the U.S.; in people under the age of 50, CRC is the top cause of cancer mortality in men and second cause in women1. Larkspur aims to shift the treatment paradigm – which hasn’t meaningfully changed in decades – by effectively activating the immune system against tumors by targeting PIP4K2C.
“PIP4K2C is part of the ‘dark kinome’ – the approximately 25% of kinases with unknown or poorly understood functions,” said Nathanael Gray, PhD, professor of chemical and systems biology at Stanford University and co-founder of Larkspur. “My co-founders and I jointly discovered that PIP4K2C acts in both cancer cells and immune cells to get tumor antigens presented to the right immune cells. Lew Cantley discovered that uniquely among the family of PI5P4K isoforms, mice that were germline knockouts of PIP4K2C broke tolerance, a hallmark of key targets that drive cancer immune evasion. Larkspur’s AACR 2024 presentation sheds further light on PIP4K2C by offering key evidence for its role as a cancer-intrinsic driver of immune evasion in both tumor and immune cells, and demonstrating the therapeutic promise of degrading the target in CRC and other solid tumors.”
Presentation details:
Published Abstract Number: 5574
Title: “Degradation of PIP4K2C by novel bivalent functional degrader LRK-A induces tumor regression in CRC”
Session Category / Session Title: Tumor Biology / Tumor-Immune System Cross-Talk
Session Date and Time: Tuesday, April 9, 1:30-5:30 pm PDT
Location / Poster Board Number: Poster Section 12 / Number 30
Presenter: Eva d’Hennezel, PhD, Director of Immunology, Larkspur Biosciences
About Larkspur Biosciences
Larkspur Biosciences is pioneering a new wave in cancer therapy that stops immune evasion where it starts: in the tumor. Larkspur’s approach targets cancer-intrinsic factors that tumors use to escape immune detection and control to develop new treatment options for patients who cannot be helped by current therapies. The company is advancing first-in-class programs designed to eliminate tumor “bottlenecks” that drive immune evasion in colorectal cancer (CRC) and beyond. LarkX, the company’s proprietary bioinformatics platform, couples machine learning with tumor genetics to discover immune evasion pathways that originate in the tumor and enrich clinical strategies for potential responders to its therapies across multiple types of cancer. Larkspur’s founders include Lewis C. Cantley, PhD, professor of medicine at Dana-Farber Cancer Institute, professor of cell biology at Harvard Medical School; Vijay K. Kuchroo, DVM, PhD, professor of neurology at Harvard Medical School, senior scientist at Brigham and Women’s Hospital; and Nathanael Gray, PhD, professor of chemical and systems biology at Stanford University.
Visit us at Larkspur.bio and follow us on LinkedIn and X.
1 American Cancer Society. Cancer Facts & Figures 2024. Atlanta: American Cancer Society; 2024.
SOURCE: Larkspur Biosciences
Post Views: 573
